M2 PHARMA-November 22, 2017-US FDA Grants Priority Review for US WorldMeds' Lofexidine
M2 EQUITYBITES-November 22, 2017-US WorldMeds wins US FDA regulatory submission & priority review for non-opioid, non-addictive lofexidine
for the management of opioid withdrawal
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced it has entered into an exclusive agreement with US WorldMeds, LLC for the commercial manufacture of lofexidine
, an investigational drug under development to mitigate symptoms associated with opioid withdrawal and facilitate completion of opioid discontinuation treatment.
Adrenergic drugs such as Clonidine and Lofexidine
have been found to help decrease excessive cravings and use of opiates.
Major disruptions of sleep during treatment of the opiate withdrawal syndrome: differences between methadone and lofexidine
Effects of THC and lofexidine
in a human laboratory model of marijuana withdrawal and relapse.
The authors concluded that buprenorphine was more effective than clonidine or lofexidine
and that buprenorphine treated patients may be more likely to complete withdrawal treatment than those treated with methadone (Gowing, Ali & White 2009).
treatment regimen compared with conventional lofexidine
and methadone treatment for in-patient opiate detoxification.
NewsScan #58 examines the latest findings in drug abuse risk, prevention, and treatment and the link between pregnant women and smoking, sexual risk behavior and teens not attending college, lofexidine
and its effects on opioid withdrawal symptoms, dopamine and striatal synaptic plasticity, substance abusersa[euro](tm) brain and its reaction to rewards, hormone processing in the brain and its relationship to drug abuse, defects in dopamine-regulating mechanism and cocaine-induced cellular stress and neural development.
This has been shown through many case reports, with at least partial response to anticholinergics (amitripryline, trihexyphenidyl, benztropine, biperiden, pirenzepine, ipratropium, scopolamine, hyoscine, atropine, and glycopyrrolate) and [alpha]-blockers (clonidine, lofexidine
, guanfacine, and terazosin).
In addition, authors explore the latest research on the use of the medications naltrexone, clonidine, and lofexidine
in the treatment of opioid dependence.
Instead, they use lofexidine
to treat addicts trying to come off opiates such as heroin.